COVID-19: Information

A note from the Chairman of the Board

“The wellbeing of our employees, of our human and animal patients and of our customers is vitally important to us. The desire to help them stay healthy is rooted in our heritage and our culture. We are doing everything we can to safeguard the continued supply of medicines to the patients who rely on us, as well as to pet and livestock owners.

We don’t have a human virology business, but that doesn’t mean that we can’t offer our science, technology and experts to initiatives that are aimed at finding medical solutions to combat the Coronavirus. We are sharing our knowledge and expertise through our active engagement in ongoing projects of institutional consortia, including the Innovative Medicines Initiative of the European Union and the German Center for Infectious Research.

In this context, we are also screening our entire molecule library of over one million compounds to identify potential molecules that could fight the virus. And there is more that we are doing, committed as we are to helping where we can.

To all of you - our employees, partners, customers, and the patients we care for - stay well."

Hubertus von Baumbach, Chairman of the Board
 

What we're doing in response to COVID-19

The increasing spread of COVID-19 has an impact on all areas of life. As a global company with more than 50,000 employees worldwide, we have taken many measures to protect the health of our employees and ensure the continued supply of our medicines to the people and animals who need them. Boehringer Ingelheim is also engaged in various initiatives to contain and cope with the global spread of COVID-19.

NP-IE-100569 | December 2021